Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT03396341

Responses to Genetic Risk Modifier Testing Among Women With BRCA1/2 Mutations

Sponsor: Memorial Sloan Kettering Cancer Center

View on ClinicalTrials.gov

Summary

The purpose of this study is to describe how women with BRCA1/2 mutations react to genetic risk modifier testing, and to examine how they make decisions about their healthcare.

Key Details

Gender

FEMALE

Age Range

25 Years - Any

Study Type

OBSERVATIONAL

Enrollment

400

Start Date

2018-01-04

Completion Date

2027-01

Last Updated

2026-02-09

Healthy Volunteers

No

Interventions

OTHER

Salvia sample

salvia sample

BEHAVIORAL

Questionnaires

Participants will complete Assessment #1 questionnaires. Participants will be contacted 1 week later (+/- 1 week) to complete Assessment #2 questionnaires. Participants will be contacted 6 months (+/- 3 weeks) following the receipt of their genetic risk modifier results to complete Assessment #3 questionnaires. Participants will be encouraged to complete Assessments #2 and #3 via email using the secure, approved REDCap system

Locations (7)

Dana Farber Cancer Institute (Data Collection Only)

Boston, Massachusetts, United States

Memorial Sloan-Kettering at Basking Ridge

Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Commack

Commack, New York, United States

Memorial Sloan Kettering Westchester

Harrison, New York, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Memorial Sloan Kettering Nassau

Uniondale, New York, United States

Abramson Cancer Center at University of Pennsylvania Medical Center (Data Collection Only)

Philadelphia, Pennsylvania, United States